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ABSTRACT
Acute renal failure (ARF) after myeloablative stem cell transplantation (SCT) is a well-established problem. Lit-
tle is known about ARF after nonmyeloablative SCT. The aim of the present study was to assess the incidence of
ARF and to analyze risk factors for ARF. Moreover, we wanted to study whether ARF influenced survival. We
performed a retrospective cohort study of 150 adults who received nonmyeloablative SCT (fludarabine 30
mg/m2/day for 3 days and/or total-body irradiation (TBI) 200 cGy). ARF was categorized into grade 0 (no
ARF), grade 1 (decrease in glomerular filtration rate$25% and# doubling in serum creatinine), grade 2 (. dou-
bling in serum creatinine), and grade 2 plus (. tripling in serum creatinine). ARF grade 2-2 plus developed in 49
of 150 patients (33%) after a median of 37 days, 14 patients (9%) had ARF grade 2 plus. No patient required di-
alysis. Risk factors at baseline for ARF grade 2-2 plus were a history of autologous transplantation (P5 .008), the
absence of vascular disease (P5 .012) lower serum creatinine (P\ .001), and higher glomerular filtration rate (P
\ .001). Acute graft-versus-host disease (aGVHD) grade III-IV was the only complication that was associated
with ARF (P 5 .035). Overall mortality at 1 year was 23%. Patients with ARF grade 2-2 plus had significantly
higher mortality compared to ARF grade 0-1 (P 5 .006). This was largely attributable to a diminished survival
in patients with ARF grade 2 plus, who had a mortality rate of 71% caused by, among others, progression of ma-
lignancy and GVHD. This makes severe ARF an indicator for decreased survival.
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Because treatment-related morbidity and mortality
(TRM) limit the success of myeloablative stem cell
transplantation (SCT), a nonmyeloablative SCT regi-
men was developed. This regimen would be suitable
for patients of older age and/or comorbidities who
were not eligible for myeloablative SCT [1]. Differences
between myeloablative and nonmyeloablative condi-
tioning are a reduction in intensities of chemotherapy
and of total-body irradiation (TBI) in the nonmyeloa-
blative approach. Because patients’ characteristics and
transplant procedures are different in the 2 regimens,
it is likely that transplant-related organ dysfunction af-
ter transplantation will be different also.
Acute renal failure (ARF) after myeloablative SCT
is a well-established problem. Incidence ranges from
27%-82%, with need for dialysis in 1%-33% ofpatients [2-11]. Mortality is increased in patients
with ARF, with mortality ranging from 75%-100%
in patients who require dialysis [2,3,5,11]. ARF after
myeloablative SCT is strongly associated with in-
fectious complications and severe organ dysfunction,
for example, hepatotoxicity with jaundice or veno-
occlusive disease (sinusoidal occlusion syndrome)
[3,4,9,11] sepsis, and use of amphotericin B [9], and
mechanical ventilation and admission to intensive
care unit [5,9]. Older patients [2,3] and patients with
hypertension before transplantation [5] have a higher
risk for the development of ARF.
Because patients eligible for nonmyeloablative
SCT are usually older and have more comorbid condi-
tions [12], ARF might occur more frequently compared
to myeloablative SCT. On the other hand, because of
less toxic conditioning regimens and a shorter period
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failure will occur less frequently [13], which could
have an effect on the incidence of ARF [14].
The aim of the present study was to assess the in-
cidence of ARF and to analyze risk factors for ARF
in a large cohort. Moreover, we wanted to study
whether ARF influenced survival.
MATERIALS AND METHODS
Patients
Between September 1, 2001, and October 1, 2005,
nonmyeloablative SCT was performed in 150 adults
aged 20-69 years, at the Department of Hematology
of the University Medical Center, Utrecht. Patient
data were collected and analyzed retrospectively using
a database and patient records through December 1,
2006. Patients gave informed consent and were treated
according to clinical protocols approved by the local
ethics review board.
The following baseline variables were noted: sex,
age, history of autologous transplantation, history of
hypertension (defined as a blood pressure $140/80
mmHg or receiving antihypertensive medication), his-
tory of vascular disease (angina pectoris, myocardial in-
farction, cerebrovascular event, and diabetes mellitus),
diagnosis of hematologic disease, malignancy risk
(low-risk malignancy: patients with acute leukemia in
first complete remission, chronic myelogenous leuke-
mia (CML) in first chronic phase and untreated severe
aplastic anemia (AA); high-risk malignancy: all other
hematologic diseases), type of transplant (matched re-
lated donor, partially matched related donor, matched
unrelated donor) and conditioning regimen.
Renal function was assessed according to serum
creatinine concentration and estimated glomerular fil-
tration rate (GFR) using the Modification of Diet in
Renal Disease equation defined as GFR5 186.3 (se-
rum creatinine)21.154  age20.203  (0.742 for women)
[15]. ARF is defined as occurrence of renal dysfunction
within 100 days after transplantation and categorized
as follows: grade 0 (or normal renal function) is equiv-
alent to a decrease in estimated GFR of\25% of the
value at time of transplantation. Grade 1 corresponds
to a \2-fold rise in serum creatinine concentration,
with a decrease in estimated GFR of.25% of the value
at time of transplantation. Grade 2 corresponds to more
than doubling in serum creatinine, without indication
for dialysis. Grade 2 plus indicates more than tripling
in serum creatinine without indication for dialysis.
Grade 3 corresponds to ARF requiering dialysis. This
classification of grades of ARF is similar to other studies
on ARF after stem cell transplantation [9,16,17].
The following variables posttransplantation were
registered: acute graft-versus-host disease (aGVHD),
cytomegalovirus (CMV) reactivation, admission tointensive care unit, hypertension, and cyclosporine
trough levels.
SCT Procedure
The nonmyeloablative conditioning regimen con-
sisted of fludarabine (30 mg/m2/day for 3 days) fol-
lowed by TBI of 200 cGy (n 5 113) or TBI alone
(n 5 37). The graft was infused after TBI on day 0.
In recipients of a histocompatibility leukocyte antigen
(HLA)-matched unrelated donor or a single HLA-an-
tigen mismatched family donor, antithymocyteglobu-
lin (Rabbit ATG, Thymoglobulin, Genzyme) was
given before fludarabine was infused, at a dose of 2
mg/kg/day for 4 days (n 5 60). All patients received
GVHD prophylaxis orally with cyclosporine and my-
cophenolate mofetil. Cyclosporine was started on day
23 at 4.5 mg/kg twice daily and continued until day
184 (n 5 89) or 1120 (n 5 61), followed by tapering
if no GVHD was present. Dose adjustments were
made to keep cyclosporine trough levels between 200
ng/mL and 400 ng/mL. Moreover, the cyclosporine
dose was lowered when creatinine rise was caused by
cyclosporine, at the discretion of the physician. Myco-
phenolate mofetil (MMF) was started 5 hours after
graft infusion at 15 mg/kg/day, with a maximum
dose of 3 g/day until day 128 (n 5 89) or 184 (n 5
61), followed by tapering if no GVHD was present.
GVHD was diagnosed according to the Seattle criteria
[18]. aGVHD grade I was treated with topical cortico-
steroids. aGVHD grade II or higher was treated with
high-dose systemic corticosteroids. Infection preven-
tion consisted of ciprofloxacin and fluconazole until
granulocyte counts exceeded 500 cell/mL. Cotrimoxa-
zol 480 mg twice daily was given for 15 months, and
valacyclovir 500 mg twice daily was given for 12
months.
Statistical Analysis
Continuous variables are displayed as the median,
with range in paracentheses. For noncontinuous vari-
ables the frequency of occurrence are given along
with the corresponding percentage. For comparison
of characteristics between groups, a chi-square test
was used to compare proportions (or Fisher’s exact
test where appropriate), and 2-sided Student’s t-test
to compare continuous outcomes.
Those parameters reaching an univariable signifi-
cance level of P # .1 were assessed for significance us-
ing multiple logistic regressions. Kaplan-Meier
survival curves were made for 1 year overall survival
(OS). Curves were compared with log-rank test. All
P-values were 2-sided, and a value of\.05 was consid-
ered statistically significant. All analysis was performed
using SPSS version 12.0 (SPSS Inc, Chicago IL).
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ARF grade 1 (decrease in GFR$25% and less than
doubling in serum creatinine) developed in 92 of 150
patients (61%) and ARF grade 2-2 plus (more than
doubling in serum creatinine, more than tripling in se-
rum creatinine) developed in 49 of 150 patients (33%),
with 14 patients (9%) ARF grade 2 plus. None of the
patients required dialysis. ARF grade 2-2 plus devel-
oped after a median of 37 days (range: 13-91).
Risk factors at baseline for ARF grade 2-2 plus
were a history of autologous transplantation
(P 5 .008), the absence of vascular disease (P 5
.012), lower serum creatinine (P\ .001), and higher
GFR (P \ .001) in univariate analysis (Table 1). In
multivariate analysis only the absence of vascular dis-
ease and higher GFR were risk factors for ARF (odds
ratio [OR] 0.1 95% confidence interval [CI] 0.012-
0.790 and OR 1.0 95% CI 1.010-1.042). Sex, age,
diagnosis, high-risk malignancy, type of transplant,
conditioning regimen, and a history of hypertension
did not differ between patients with ARF grade 2-2
plus and patients with grade 0 or 1.
aGVHD grade III-IV was the only complication
occurring in the first 100 days that was associated
with ARF grade 2-2 plus (P 5 .035). aGVHD 0-II,
the occurrence of hypertension, CMV reactivation,
or admission to the intensive care unit was not associ-
ated with ARF grade 2-2 plus. Moreover, the immune
suppression regimen (cyclosporine 184 and MMF
128 or cyclosporine1120 and mycophenolate mofetil
184) and cyclosporine trough levels (mean of all levels,
level at highest creatinine, occurrence of levels $400
ng/mL) did not differ between the groups with or
without ARF grade 2-2 plus. None of the patients de-
veloped thrombotic thrombocytopenic purpura or si-
nusoidal occlusion syndrome.
ARF in patients with ARF grade 2 plus was caused
by: (1) progression of lymphoma in 3 patients, (2) se-
vere diarrhea from GVHD grade III-IV in 5 patients,
(3) nephrotoxic medication (ganciclovir and/or cyclo-
sporine) in 4 patients, (4) multiorgan failure on the in-
tensive care unit in 1 patients with sepsis, and (5)
dehydration because of pseudomembranous colitis in
1 patient.
Risk factors at baseline for ARF grade 2 plus were
higher GFR (P 5 .045). Complications that were
associated with ARF grade 2 plus were aGVHD grade
III-IV (P5 .014) and CMV reactivation (p5 .018). Hy-
pertension occurred significantly less (P5 .019) in pa-
tients with ARF grade 2 plus. These associations reflect
that major causes of ARF grade 2 plus are: severe
GVHD with diarrhea and dehydration, which causes
hypotension and risk for CMV reactivation because
of treatment of GVHD with high-dose prednisolon.
Analysis of patients without ARF (grade 0) showed
significantly lower GFR and higher creatinine atbaseline, opposite to patients with ARF grade 2-2
plus (data not shown).
Overall mortality at 1 year was 23%. Patients with
ARF grade 2-2 plus had a significant higher mortality
rate at 1 year (37%) than patients with ARF grade 0-
1 (16%) (P 5 .001 and P 5 .006) (Table 1). This was
largely attributable to a diminished survival in patients
with ARF grade 2 plus, who had a mortality rate of 71%
at 1 year. Kaplan-Meier survival curves are shown in
Figure 1, with a significantly decreased overall survival
(OS) in patients with ARF grade 2 plus compared to
all other patients (P\ .001). There was no significant
survival benefit for patients without ARF (grade 0).
There was no significantly difference between
treatment related mortality (n 5 6) or relapse (n 5 4)
as cause of death for patients with ARF grade 2 plus.
Of the 10 patients with ARF grade 2 plus who died,
3 died of progression of lymphoma that also caused
ARF, 4 patients died of GVHD, which also caused
ARF, 1 patient died on the intensive care unit of sepsis,
which also caused ARF, 1 patient had a sudden death
with unknown cause after recovery of ARF because
of pseudomembranous colitis, and 1 patient died of
relapse of AML after ARF due to cyclosporine. Re-
lapse-related mortality curves and TRM curves are
shown in Figures 2 and 3. Patients with ARF grade 2
plus had a significant shorter survival after relapse
compared to all other patients (P 5 .026). There was
no significant difference in TRM within 1 year be-
tween the patients with the different grades of ARF.
DISCUSSION
In this large single-center cohort of recipients of
nonmyeloablative SCT, 33% of patients developed
ARF grade 2-2 plus. The incidence of ARF after mye-
loablative SCT (conditioning with 2 days cyclofosfa-
mide 60 mg/m2/day and 2 days TBI of 600 cGy/day)
was reported as 49% in the same center [5]. More im-
portantly, although 14 patients (9%) developed more
than tripling in serum creatinine, none of the patients
required dialysis. Parikh et al. [19] found in a multicen-
ter study on nonmyeloablative SCT an incidence of
ARF and dialysis of 40% and 4%, respectively, and
in a single-center study an incidence of 44% and 3%,
respectively [19]. This was lower compared to the
myeloablative cohort [20]. In a recent small study of
26 recipients of nonmyeloablative SCT, only 19% de-
veloped ARF, with 1 patient requiring dialysis [21].
This indicates that incidence of ARF after nonmyeloa-
blative SCT is lower than after myeloablative SCT.
The main reason for lower incidence of ARF is most
likely the less toxic conditioning regimen and shorter
neutropenia period, which diminishes the incidence
of posttransplant complications and infections. In
this cohort, no patient developed sinusoidal occlusion
syndrome, a complication strongly associated with
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All Patients (%) ARF Grade 2 (%) ARF Grade 0 and 1 (%) P Multivariate OR (95%CI)
Sex ns
Male 98 (65.3) 29 (59.2) 69 (68.3)
Female 52 (34.7) 20 (40.8) 32 (31.7)
Age 56.5 range 20-69 58 range 20-66 56 range 20-69 ns
History
Autologous 59 (39.3) 27 (55.1) 32 (31.7) 0.008
Hypertension 56 (37.3) 19 (38.8) 37 (36.6) ns
Vascular disease 17 (11.3) 1 (2.0) 16 (15.8) .012 0.1 (0.012-0.79)
Diagnosis ns
Acute myelogenous leukemia 26 (17.3) 8 (16.3) 18 (17.8)
Acute lymphoblastic leukemia 5 (3.3) 3 (6.1) 2 (2.0)
Chronic myelogenous leukemia 5 (3.3) 1 (2.0) 4 (4.0)
Severe aplastic anemia 6 (4.0) 0 (0) 6 (5.9)
Multiple myeloma 57 (38.0) 22 (44.9) 35 (34.7)
Non-Hodgkin lymphoma 25 (16.7) 6 (12.2) 19 (18.8)
Chronic lymphatic leukemia 10 (6.7) 3 (6.1) 7 (6.0)
Myelodysplastic syndrome 8 (5.3) 5 (10.2) 3 (3.0)
Other 8 (5.3) 1 (2.0) 7 (6.9)
Risk ns
High-risk malignancy 123 (82) 41 (83.7) 82 (81.2)
Low-risk malignancy 27 (18) 8 (16.3) 19 (18.8)
Type of transplant ns
Matched related donor 96 (64.0) 32 (65.3) 64 (63.4)
Partially matched
related donor
8 (5.3) 2 (4.1) 6 (5.9)
Matched unrelated donor 46 (30.7) 15 (30.6) 31 (30.7)
Mismatch 21 (14.0) 6 (12.2) 15 (14.9)
Conditioning ns
Fludarabine 1 (0.7) 1 (2) 0 (0)
Fludarabine/TBI 54 (36) 14 (28.6) 40 (39.6)
Fludarabine/TBI/ATG 58 (38.7) 17 (34.7) 41 (40.6)
TBI 37 (24.7) 17 (34.7) 20 (19.8)
Renal function
Estimated GFR (mL/min/1.73 m2) 82 (35-187) 92 (44-187) 78 (35-142) \.001 1.0 (1.01-1.042)
Creatinine (mmoll/L) median (range) 80 (46-178) 72 (46-123) 85 (57-178) \.001
Complications
Hypertension after transplantation 42 (28.0) 11 (22.4) 31 (30.7) ns
CMV reactivation 19 (12.7) 8 (16.3) 11 (10.9) ns
ICU admission 6 (4) 3 (6.1) 3 (3) ns
aGVHD grade 0-I 80 (53.3) 22 (44.9) 58 (57.4) ns
aGVHD grade II 45 (30) 14 (28.6) 31 (30.7) ns
aGVHD III-IV 25 (16.7) 13 (26.5) 12 (11.9) .035
Cyclosporine trough
level .400 ng/L
77 (52) 31 (63.3) 46 (46.5) ns
Outcome
Death at 6 months 23 (15.3) 15 (30.6) 8 (7.9) .001
Death at 12 months 34 (22.7) 18 (36.7) 16 (15.8) .006
Death from relapse
at 12 months
18 (12.0) 8 (16.3) 10 (9.9) ns
TRM at 12 months 16 (10.7) 10 (20.4) 6 (5.9) ns
TBI indicates total-body irradiation; ATG, antithymocyte globulin; GFR, glomerular filtration rate; CMV, cytomegalovirus; ICU, intensive care unit;
aGVHD: acute graft-versus-host disease; TRM, treatment-related mortality; OR, odds ratio; CI, confidence interval; ARF, acute renal failure.
Hypertension: tension .140/90 mmHg.
Vascular disease (angina pectoris, myocardial infarction, cerebrovascular event, and diabetes mellitus).
Low-risk malignancy: patients with acute leukemia in first complete remission, chronic myelogenous leukemia in first chronic phase and un-
treated severe aplastic anemia. High-risk malignancy: all other hematological diseases.ARF after SCT following myeloablative conditioning
[2-4,11] or mildly reduced intensity conditioning [21].
One of the risk factors for ARF in our study cohort
was lower creatinine and a higher estimated GFR at
baseline. This is in accordance with previous studies[4,19]. This is most probably affected by the definition
of ARF (more than doubling in serum creatinine) used
in all the studies on ARF after SCT. The absolute
changes required for doubling of serum creatinine is
lower for persons with lower creatinine. Patients
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of ARF grade 2-2 plus sooner. Because serum creati-
nine is the most important parameter in equations
for estimating GFR (both in Modification of Diet in
Renal Disease equation and Cockroft and Gault equa-
tion), patients with ARF who have lower creatinine at
baseline will therefore have higher GFR at baseline.
Another explanation for higher incidence of ARF for
patients with lower creatinine at baseline may be that
the rise in serum creatinine is overlooked because se-
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Figure 1. OS curves for the different grades of ARF.
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Figure 2. Kaplan-Meier survival curve for the different grades of
ARF in patients with relapse of disease within 1 year (n 5 23).rum creatinine remains in the normal range for healthy
individuals.
Surprisingly, patients with vascular disease had less
risk for development of ARF. A possible reason for this
is prudence of the physician in monitoring cyclospor-
ine levels and creatinine in this vulnerable patient
group. Preexisting diabetes was not associated with
ARF in another study [19]. This confirms that non-
myeloablative SCT is suitable for patients with diabe-
tes not eligible for myeloablative transplantation, with
regard to renal function.
In our study, neither mean of all cyclosporine
trough levels, level at highest creatinine, nor occur-
rence of levels $400 ng/mL corresponded to the de-
velopment of ARF. This is remarkable, because
elevated serum creatinine levels are often ascribed to
cyclosporine [1,12]. Although Parikh et al. [19] did
not find a correlation between cyclosporine and ARF
in univariate analysis, by chart review cyclosporine ap-
peared to be related to grade 2 ARF in almost all cases
and ARF resolved with lowering of the dose. Also, in
our 14 patients with severe ARF, cyclosporine ap-
peared to be the cause in 3 patients. An explanation
for the discrepancy between clinical impression and
statistical analysis of the effect of cyclosporine on renal
function may be the variability in cyclosporine trough
levels within a patient and the transient effect of cyclo-
sporine on renal dysfunction. Also, other studies failed
to correlate cyclosporine to ARF [4,5,11,19].
The only complication after SCT associated with
ARF was severe aGVHD grade III or IV, which is con-
sistent with another study [3]. However, less severe
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Figure 3. Kaplan-Meier mortality curves for the different grades of ARF
in patients with treatment related mortality (TRM) within 1 year (n5 16).
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with previous studies [4,11,19]. This makes GVHD of
the kidneys less likely an explanation for the associa-
tion of severe aGVHD with ARF. Dehydration be-
cause of diarrhea in patients with severe aGVHD
is most likely the cause of ARF, which was seen in
5 of our patients with more than tripling of serum
creatinine.
In a previous study a risk factor for ARF was hema-
topoietic stem cells from bone marrow compared to
stem cells from peripheral blood [19]. This was, how-
ever, not confirmed in another study [20]. Because all
our patients received hematopoietic stem cells from
peripheral blood, we could not analyze this issue. Fe-
male sex and high-risk malignancy were risk factors
for ARF in 1 study [20], but not in another [19], and
also not in our study, making it questionable whether
female sex and high-risk malignancies predispose for
ARF.
Mortality at 1 year was more than twice as high in
patients with ARF grade 2-2 plus compared to patients
with ARF grade 0-1. This was largely attributable to
a diminished survival in patients with ARF grade 2
plus, who had a mortality rate of 71%. Parikh et al.
[19]. also found significantly higher mortality in pa-
tients with ARF after transplantation, but this was
largely attributable to ARF that required dialysis.
Mortality in patients requiring dialysis after myeloa-
blative transplantation is known to be very high
[2,3,5,11]. In our study, survival was decreased in pa-
tients with ARF grade 2 plus, despite the fact that
none of our patients required dialysis. Almost all
ARF grade 2 plus died of conditions that also caused
ARF (eg, progression of lymphoma or severe
aGVHD). This indicates that ARF grade 2 plus is
not the cause of increased mortality, but a strong indi-
cator for decreased survival in patients with ARF sec-
ondary to other causes.
Adequate monitoring of serum creatinine remains
crucial in detecting drug-induced nephrotoxicity and
to stop or adjust the dose of nephrotoxic drugs where
possible. Because aGVHD grade III is a major compli-
cation associated with ARF, prevention and treatment
of severe GVHD is a very important issue in diminish-
ing the occurrence of ARF.
In conclusion, of all patients after nonmyeloabla-
tive SCT one-third will develop ARF. About 10% of
patients will develop a severe ARF with high mortality
caused by relapse, severe GVHD, or other complica-
tions. This makes severe ARF an indicator for de-
creased survival.
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